- Theralase Technologies (TSXV:TLT) has been awarded a Canadian patent for a game-changing cancer vaccine
- The patent protects the company’s Photo Dynamic Compounds technology, which trains a patient’s immune system to destroy particular cancer cells
- Theralase Technologies is researching and developing light-activated drug formulations to destroy various cancers, bacteria and viruses
- Theralase stock has given back 38.46 per cent year-over-year, and 70.91 per cent over the past five years
Theralase Technologies (TSXV:TLT) has been awarded a Canadian patent for a game-changing cancer vaccine.
The patent is entitled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same.”
It protects the company’s Photo Dynamic Compounds (PDC) technology, which inactivates a sample of a patient’s cancer outside of the body, enhancing it with new programming to train the immune system to destroy particular cancer cells. The inactivated cancer is then reinjected to get to work.
Theralase already benefits from a U.S. patent for PDC technology issued in October 2022, while a European Union patent is currently pending. The company’s robust PDC pipeline includes:
- A Phase II registration clinical study for bladder cancer treatment Ruvidar slated for completion in 2026
- Plans to launch a Phase Ib clinical study for brain cancer and lung cancer in 2024
- Pending completion of a toxicology analysis
- The ability to treat various liquid cancers such as leukemia, lymphoma and myeloma with its new patented vaccine
Pending regulatory approval, the company’s efforts in the bladder cancer space could grant it access to a target market that generates US$1 billion to US$7 billion per year.
Management insights
“The issuance of an additional patent for our cancer vaccine technology represents a significant opportunity for patients diagnosed with blood-related cancers, which are difficult, if not impossible, to treat,” Dr. Arkady Mandel, Theralase’s chief scientific officer, and the inventor of the new patent, said in a statement. “Our primary focus has been on the research and development of technology to destroy solid-core tumours, such as bladder, brain and lung cancers; however, this new patent allows the company the opportunity to explore the treatment of various liquid cancers.”
“The possibilities and opportunities of our PDC technology continue to grow at a rapid pace,” added Roger DuMoulin-White, Theralase’s president and chief executive officer. “The company plans to become properly financed this year through various equity and debt instruments to allow the company the opportunity to commence new clinical studies focused on the destruction of both solid-core and liquid cancers. I am excited about the opportunities available to the company as a result of these new patents, as it significantly increases the opportunity for our PDC technology to treat patients inflicted with a wide range of cancers.”
About Theralase Technologies
Theralase Technologies is a clinical-stage pharmaceutical company researching and developing light-activated compounds, their associated drug formulations and the light systems that activate them, to destroy various cancers, bacteria and viruses.
Theralase Technologies (TSXV:TLT) last traded at C$0.16 per share. The stock has given back 38.46 per cent year-over-year, and 70.91 per cent over the past five years.
Join the discussion: Learn what other investors are saying about this stock on the Theralase Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.